BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545. [PMID: 26284562 DOI: 10.1038/nrgastro.2015.135] [Cited by in Crossref: 193] [Cited by in F6Publishing: 179] [Article Influence: 27.6] [Reference Citation Analysis]
Number Citing Articles
1 Chen L, Xu CJ, Wu W, Ding BJ, Liu ZJ. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. J Dig Dis 2021;22:408-18. [PMID: 34048629 DOI: 10.1111/1751-2980.13026] [Reference Citation Analysis]
2 Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, Gutierrez AM, Ciorba MA. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. J Crohns Colitis. 2016;10:402-409. [PMID: 26681763 DOI: 10.1093/ecco-jcc/jjv226] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 9.7] [Reference Citation Analysis]
3 Zhang W, Michalowski CB, Beloqui A. Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Front Bioeng Biotechnol 2021;9:675194. [PMID: 34150733 DOI: 10.3389/fbioe.2021.675194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang X, Fan Y, Yan J, Yang M. Engineering polyphenol-based polymeric nanoparticles for drug delivery and bioimaging. Chemical Engineering Journal 2022;439:135661. [DOI: 10.1016/j.cej.2022.135661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-biroulet L. Treatment Persistence for Infliximab Versus Adalimumab in Crohnʼs Disease: A 14-Year Single-Center Experience. Inflammatory Bowel Diseases 2017;23:976-85. [DOI: 10.1097/mib.0000000000001072] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
6 Anderton H, Wicks IP, Silke J. Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease. Nat Rev Rheumatol 2020;16:496-513. [PMID: 32641743 DOI: 10.1038/s41584-020-0455-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
7 Qi S, Li Y, Dai Z, Xiang M, Wang G, Wang L, Wang Z. Uhrf1-Mediated Tnf-α Gene Methylation Controls Proinflammatory Macrophages in Experimental Colitis Resembling Inflammatory Bowel Disease. J I 2019;203:3045-53. [DOI: 10.4049/jimmunol.1900467] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
8 Di Domenicantonio R, Trotta F, Cascini S, Agabiti N, Kohn A, Gasbarrini A, Davoli M, Addis A. Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clin Epidemiol 2018;10:203-13. [PMID: 29440933 DOI: 10.2147/CLEP.S150030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Sakisaka H, Takedatsu H, Mitsuyama K, Mochizuki S, Sakurai K, Sakisaka S, Hirai F. Topical Therapy with Antisense Tumor Necrosis Factor Alpha Using Novel β-Glucan-Based Drug Delivery System Ameliorates Intestinal Inflammation. Int J Mol Sci 2020;21:E683. [PMID: 31968666 DOI: 10.3390/ijms21020683] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
10 Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. Inflamm Bowel Dis 2021;27:182-9. [PMID: 32083291 DOI: 10.1093/ibd/izaa036] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
11 Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 [DOI: 10.12998/wjcc.v9.i36.11285] [Reference Citation Analysis]
12 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Te Velde AA, Bezema T, van Kampen AH, Kraneveld AD, 't Hart BA, van Middendorp H, Hack EC, van Montfrans JM, Belzer C, Jans-Beken L, Pieters RH, Knipping K, Huber M, Boots AM, Garssen J, Radstake TR, Evers AW, Prakken BJ, Joosten I. Embracing Complexity beyond Systems Medicine: A New Approach to Chronic Immune Disorders. Front Immunol 2016;7:587. [PMID: 28018353 DOI: 10.3389/fimmu.2016.00587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
14 Yang H, Li B, Guo Q, Tang J, Peng B, Ding N, Li M, Yang Q, Huang Z, Diao N, Zhu X, Deng J, Guo H, Hu P, Chao K, Gao X. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther 2022. [PMID: 35141914 DOI: 10.1111/apt.16802] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Morel PA, Lee REC, Faeder JR. Demystifying the cytokine network: Mathematical models point the way. Cytokine 2017;98:115-23. [PMID: 27919524 DOI: 10.1016/j.cyto.2016.11.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
16 Borren NZ, Tan W, Jess AT, Li PM, Garber JJ, Luther J, Colizzo FP, Khalili H, Ananthakrishnan AN. Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort Study. Dig Dis Sci 2020;65:3672-8. [PMID: 32617768 DOI: 10.1007/s10620-020-06442-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
17 Yang HH, Huang Y, Zhou XC, Wang RN. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis. World J Clin Cases 2022; 10(18): 6091-6104 [DOI: 10.12998/wjcc.v10.i18.6091] [Reference Citation Analysis]
18 Doeve BH, van de Meeberg MM, van Schaik FD, Fidder HH. A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease: What Can We Learn From Randomized and Nonrandomized Studies? Journal of Clinical Gastroenterology 2020;Publish Ahead of Print. [DOI: 10.1097/mcg.0000000000001393] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. J Crohns Colitis 2020;14:1090-102. [PMID: 32119090 DOI: 10.1093/ecco-jcc/jjaa039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
20 Berger AA, Liu Y, Jin K, Kaneb A, Welschmeyer A, Cornett EM, Kaye AD, Imani F, Khademi SH, Varrassi G, Viswanath O, Urits I. Efficacy of Acupuncture in the Treatment of Chronic Abdominal Pain. Anesth Pain Med 2021;11:e113027. [PMID: 34336622 DOI: 10.5812/aapm.113027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Yu S, Li S, Henke A, Muse ED, Cheng B, Welzel G, Chatterjee AK, Wang D, Roland J, Glass CK, Tremblay M. Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases. FASEB J 2016;30:2570-9. [PMID: 27025962 DOI: 10.1096/fj.201600244R] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
22 Dmochowska N, Wardill HR, Hughes PA. Advances in Imaging Specific Mediators of Inflammatory Bowel Disease. Int J Mol Sci 2018;19:E2471. [PMID: 30134572 DOI: 10.3390/ijms19092471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
23 Honda M, Kubes P. Neutrophils and neutrophil extracellular traps in the liver and gastrointestinal system. Nat Rev Gastroenterol Hepatol 2018;15:206-21. [PMID: 29382950 DOI: 10.1038/nrgastro.2017.183] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 21.5] [Reference Citation Analysis]
24 Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141-150. [PMID: 27832357 DOI: 10.1007/s00535-016-1283-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
25 Borren NZ, Tan W, Colizzo FP, Luther J, Garber JJ, Khalili H, van Der Woude CJ, Ananthakrishnan AN. Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. Journal of Crohn's and Colitis 2020;14:309-15. [DOI: 10.1093/ecco-jcc/jjz148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
26 Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741-1755. [PMID: 27914655 DOI: 10.1016/s0140-6736(16)31711-1] [Cited by in Crossref: 615] [Cited by in F6Publishing: 285] [Article Influence: 102.5] [Reference Citation Analysis]
27 Eder P, Korybalska K, Łykowska-szuber L, Stawczyk-eder K, Krela-kaźmierczak I, Łuczak J, Czepulis N, Linke K, Witowski J. An increase in serum tumour necrosis factor-α during anti-tumour necrosis factor-α therapy for Crohn's disease – A paradox or a predictive index? Digestive and Liver Disease 2016;48:1168-71. [DOI: 10.1016/j.dld.2016.06.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
28 Haghnejad V, Le Berre C, Dominique Y, Zallot C, Guillemin F, Peyrin-biroulet L. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Digestive and Liver Disease 2020;52:281-8. [DOI: 10.1016/j.dld.2019.09.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Hermanns HM, Wohlfahrt J, Mais C, Hergovits S, Jahn D, Geier A. Endocytosis of pro-inflammatory cytokine receptors and its relevance for signal transduction. Biol Chem 2016;397:695-708. [PMID: 27071147 DOI: 10.1515/hsz-2015-0277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Chapuis-Biron C, Bourrier A, Nachury M, Nancey S, Bouhnik Y, Serrero M, Armengol-Debeir L, Buisson A, Tran-Minh ML, Zallot C, Fumery M, Bouguen G, Abitbol V, Viennot S, Chanteloup E, Rajca S, Dib N, Parmentier AL, Peyrin-Biroulet L, Vuitton L;  GETAID BioLAP Study Group. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther. 2020;51:719-727. [PMID: 32080886 DOI: 10.1111/apt.15665] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
31 Ni Y, Rosier BJHM, van Aalen EA, Hanckmann ETL, Biewenga L, Pistikou AM, Timmermans B, Vu C, Roos S, Arts R, Li W, de Greef TFA, van Borren MMGJ, van Kuppeveld FJM, Bosch BJ, Merkx M. A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays. Nat Commun 2021;12:4586. [PMID: 34321486 DOI: 10.1038/s41467-021-24874-3] [Reference Citation Analysis]
32 Hidalgo-Garcia L, Galvez J, Rodriguez-Cabezas ME, Anderson PO. Can a Conversation Between Mesenchymal Stromal Cells and Macrophages Solve the Crisis in the Inflamed Intestine? Front Pharmacol 2018;9:179. [PMID: 29559912 DOI: 10.3389/fphar.2018.00179] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
33 Currie KS, Patel L, Sedillo KF. Small-molecule agents for the treatment of inflammatory bowel disease. Bioorganic & Medicinal Chemistry Letters 2019;29:2034-41. [DOI: 10.1016/j.bmcl.2019.06.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Pu D, Zhang Z, Feng B. Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases. Front Pharmacol 2022;13:906419. [DOI: 10.3389/fphar.2022.906419] [Reference Citation Analysis]
35 Buchbender M, Fehlhofer J, Proff P, Möst T, Ries J, Hannig M, Neurath MF, Gund M, Atreya R, Kesting M. Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients-a preliminary study. Clin Oral Investig 2021. [PMID: 34383142 DOI: 10.1007/s00784-021-04093-2] [Reference Citation Analysis]
36 Villanacci V, Cadei M, Lanzarotto F, Ricci C, Antonelli E, Cannatelli R, Gulotta T, Fontana L, Pasquali V, Sigala S, Salviato T, Nascimbeni R, Bassotti G. Localization of TNF alpha in ileocolonic biopsies of patients with inflammatory bowel disease. Ann Diagn Pathol 2019;38:20-5. [PMID: 30388432 DOI: 10.1016/j.anndiagpath.2018.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Solomon S, Park E, Picoraro JA. Making Decisions about Dietary Therapy in Inflammatory Bowel Disease. GastrointestDisord 2020;2:353-65. [DOI: 10.3390/gidisord2040032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Chen ML, Sundrud MS. Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22:1157-1167. [PMID: 26863267 DOI: 10.1097/mib.000000 0000000714] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Mishra J, Stubbs M, Kuang L, Vara N, Kumar P, Kumar N, Subramanian VS. Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering. Mediators of Inflammation 2022;2022:1-15. [DOI: 10.1155/2022/9621668] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
40 Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(11): 1932-1943 [PMID: 28373759 DOI: 10.3748/wjg.v23.i11.1932] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
41 Chen C, Hartzema AG, Xiao H, Wei Y, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM. Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. Inflammatory Bowel Diseases 2019;25:1417-27. [DOI: 10.1093/ibd/izz001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 38] [Article Influence: 17.3] [Reference Citation Analysis]
42 Hmar EBL, Paul S, Boruah N, Sarkar P, Borah S, Sharma HK. Apprehending Ulcerative Colitis Management With Springing Up Therapeutic Approaches: Can Nanotechnology Play a Nascent Role? Curr Pathobiol Rep 2021;9:9-32. [DOI: 10.1007/s40139-020-00218-6] [Reference Citation Analysis]
43 Pouillon L, Baumann C, Rousseau H, Choukour M, Andrianjafy C, Danese S, Peyrin-biroulet L. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. Inflammatory Bowel Diseases 2019;25:945-54. [DOI: 10.1093/ibd/izy322] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
44 Almario CV, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, Melmed GY, Spiegel BMR. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. American Journal of Gastroenterology 2018;113:58-71. [DOI: 10.1038/ajg.2017.470] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
45 Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
46 Quirós M, Nusrat A. Contribution of Wound-Associated Cells and Mediators in Orchestrating Gastrointestinal Mucosal Wound Repair. Annu Rev Physiol 2019;81:189-209. [PMID: 30354933 DOI: 10.1146/annurev-physiol-020518-114504] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
47 Farkas K, Molnár T. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease. Immunotherapy 2018;10:107-17. [PMID: 29124994 DOI: 10.2217/imt-2017-0107] [Reference Citation Analysis]
48 Bartneck M, Wang J. Therapeutic Targeting of Neutrophil Granulocytes in Inflammatory Liver Disease. Front Immunol 2019;10:2257. [PMID: 31616430 DOI: 10.3389/fimmu.2019.02257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
49 Kawamoto A, Nagata S, Anzai S, Takahashi J, Kawai M, Hama M, Nogawa D, Yamamoto K, Kuno R, Suzuki K, Shimizu H, Hiraguri Y, Yui S, Oshima S, Tsuchiya K, Nakamura T, Ohtsuka K, Kitagawa M, Okamoto R, Watanabe M. Ubiquitin D is Upregulated by Synergy of Notch Signalling and TNF-α in the Inflamed Intestinal Epithelia of IBD Patients. Journal of Crohn's and Colitis 2019;13:495-509. [DOI: 10.1093/ecco-jcc/jjy180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
50 Woźniak M, Kurnatowska I, Małecka-Panas E, Talar-Wojnarowska R. Leukocytapheresis in patients with inflammatory bowel diseases. Prz Gastroenterol 2021;6:99-105. [PMID: 34276835 DOI: 10.5114/pg.2021.106658] [Reference Citation Analysis]
51 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
52 Liu J, Lai X, Bao Y, Xie W, Li Z, Chen J, Li G, Wang T, Huang W, Ma Y, Shi J, Zhao E, Xiang AP, Liu Q, Chen X. Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells. Front Immunol 2022;13:853894. [DOI: 10.3389/fimmu.2022.853894] [Reference Citation Analysis]
53 Weng MT, Tung CC, Chang YT, Leong YL, Wang YT, Wong JM, Wei SC. Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015. J Clin Med 2018;7:E394. [PMID: 30373275 DOI: 10.3390/jcm7110394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
54 Jiang H, Shen J, Ran Z. Epithelial-mesenchymal transition in Crohn's disease. Mucosal Immunol. 2018;11:294-303. [PMID: 29346350 DOI: 10.1038/mi.2017.107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
55 Alipour O, Gualti A, Shao L, Zhang B. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease. BMC Gastroenterol 2021;21:312. [PMID: 34344314 DOI: 10.1186/s12876-021-01883-6] [Reference Citation Analysis]
56 Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. Drugs Aging 2017;34:859-68. [PMID: 29170864 DOI: 10.1007/s40266-017-0498-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
57 van der Laan JJH, van der Waaij AM, Gabriëls RY, Festen EAM, Dijkstra G, Nagengast WB. Endoscopic imaging in inflammatory bowel disease: current developments and emerging strategies. Expert Rev Gastroenterol Hepatol 2021;15:115-26. [PMID: 33094654 DOI: 10.1080/17474124.2021.1840352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
58 Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis 2021;15:840-59. [PMID: 32915970 DOI: 10.1093/ecco-jcc/jjaa186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Pagnini C, Siakavellas SI, Bamias G. Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. Gastroenterol Res Pract 2018;2018:6317057. [PMID: 30116266 DOI: 10.1155/2018/6317057] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
60 Sherlock ME, Zachos M, Issenman RM, Mulder DJ. Clinical and Laboratory Characteristics Are Associated With Biologic Therapy Use in Pediatric Inflammatory Bowel Disease: A Retrospective Cohort Study. J Can Assoc Gastroenterol 2021;4:e92-e100. [PMID: 34617006 DOI: 10.1093/jcag/gwaa033] [Reference Citation Analysis]
61 Chen S, Liu H, Li Z, Tang J, Huang B, Zhi F, Zhao X. Epithelial PBLD attenuates intestinal inflammatory response and improves intestinal barrier function by inhibiting NF-κB signaling. Cell Death Dis 2021;12:563. [PMID: 34059646 DOI: 10.1038/s41419-021-03843-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Cruz-Lebrón A, D'argenio Garcia L, Talla A, Joussef-Piña S, Quiñones-Mateu ME, Sékaly RP, de Carvalho KIL, Levine AD. Decreased Enteric Bacterial Composition and Diversity in South American Crohn's Disease Vary With the Choice of Treatment Strategy and Time Since Diagnosis. J Crohns Colitis 2020;14:791-800. [PMID: 31758685 DOI: 10.1093/ecco-jcc/jjz189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Li Y, Liu XJ, Su SL, Yan H, Guo S, Qian DW, Duan JA. Evaluation of Anti-Inflammatory and Antioxidant Effectsof Chrysanthemum Stem and Leaf Extract on Zebrafish Inflammatory Bowel Disease Model. Molecules 2022;27:2114. [PMID: 35408512 DOI: 10.3390/molecules27072114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500. [PMID: 28973005 DOI: 10.1371/journal.pone.0185500] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 11.2] [Reference Citation Analysis]
65 Lenti MV, Levison S, Eliadou E, Willert R, Kemp K, Carter A, Stansfield C, Assadsangabi A, Singh S, Crooks B, Tattersall S, Fairhurst F, Kenneth C, Subramanian S, Probert C, Storey D, Gregg B, Smith P, Liu E, Limdi JK, Johnston A, Hamlin PJ, Selinger CP. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. Dig Liver Dis 2018;50:1299-304. [PMID: 30077465 DOI: 10.1016/j.dld.2018.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
66 Magro F, Afonso J, Lopes S, Coelho R, Gonçalves R, Caldeira P, Lago P, de Sousa HT, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Andrade P, Soares JB, Carvalho D, Sousa P, Meira T, Lopes J, Moleiro J, Dias CC, Falcão A, Geboes K, Carneiro F; Portuguese IBD Study Group (GEDII). Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation. EBioMedicine 2017;21:123-30. [PMID: 28629912 DOI: 10.1016/j.ebiom.2017.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Pouillon L, Van Stappen J, Bossuyt P, Danese S, Peyrin-biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology 2018;32-33:17-25. [DOI: 10.1016/j.bpg.2018.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
68 Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol 2020;18:2179-2191.e6. [PMID: 31945470 DOI: 10.1016/j.cgh.2020.01.008] [Cited by in Crossref: 100] [Cited by in F6Publishing: 75] [Article Influence: 50.0] [Reference Citation Analysis]
69 Sarazin A, Dendooven A, Delbeke M, Gatault S, Pagny A, Standaert A, Rousseaux C, Desreumaux P, Dubuquoy L, Capron M. Treatment with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: Decrease of intestinal inflammation associated with a down regulation of Th1/Th17 responses. PLoS One 2018;13:e0209681. [PMID: 30592734 DOI: 10.1371/journal.pone.0209681] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
70 Mahlich J, May M, Feig C, Straub V, Schmelz R. Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis. Crohn's & Colitis 360 2021;3:otab011. [DOI: 10.1093/crocol/otab011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Kim JH, Cheon JH, Park Y, Lee HJ, Park SJ, Kim TI, Kim WH. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol 2016;51:1069-74. [PMID: 26895215 DOI: 10.3109/00365521.2016.1150503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
72 Stevens BW, Borren NZ, Velonias G, Conway G, Cleland T, Andrews E, Khalili H, Garber JG, Xavier RJ, Yajnik V, Ananthakrishnan AN. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Dig Dis Sci 2017;62:197-206. [PMID: 27796768 DOI: 10.1007/s10620-016-4356-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
73 Jung YS, Han M, Park S, Cheon JH. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Dig Dis Sci 2020;65:1436-44. [PMID: 31677070 DOI: 10.1007/s10620-019-05867-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
74 Qasem A, Naser SA. TNFα inhibitors exacerbate Mycobacterium paratuberculosis infection in tissue culture: a rationale for poor response of patients with Crohn's disease to current approved therapy. BMJ Open Gastroenterol 2018;5:e000216. [PMID: 30073091 DOI: 10.1136/bmjgast-2018-000216] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
75 Bonovas S, Peyrin-biroulet L, Danese S. Clinical development of biologicals and biosimilars - safety concerns. Expert Review of Clinical Pharmacology 2017;10:567-9. [DOI: 10.1080/17512433.2017.1293522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
76 Chen ML, Sundrud MS. Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22:1157-1167. [PMID: 26863267 DOI: 10.1097/mib.0000000000000714] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 14.8] [Reference Citation Analysis]
77 Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B 2021;11:941-60. [PMID: 33996408 DOI: 10.1016/j.apsb.2020.12.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 28.0] [Reference Citation Analysis]
78 Xie C, Yan W, Quan R, Chen C, Tu L, Hou X, Fu Y. Interleukin-38 is elevated in inflammatory bowel diseases and suppresses intestinal inflammation. Cytokine 2020;127:154963. [PMID: 31927461 DOI: 10.1016/j.cyto.2019.154963] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
79 Du Y, Rong L, Cong Y, Shen L, Zhang N, Wang B. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease. Expert Opin Ther Targets 2021;25:191-209. [PMID: 33682588 DOI: 10.1080/14728222.2021.1901079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
80 Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017;23:1510-1515. [PMID: 28816757 DOI: 10.1097/mib.0000000000001231] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
81 Calenda G, Keawvichit R, Arrode-Brusés G, Pattanapanyasat K, Frank I, Byrareddy SN, Arthos J, Cicala C, Grasperge B, Blanchard JL, Gettie A, Reimann KA, Ansari AA, Martinelli E. Integrin α4β7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques. J Immunol 2018;200:810-20. [PMID: 29196458 DOI: 10.4049/jimmunol.1701150] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
82 Russi L, Scharl M, Rogler G, Biedermann L. The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. Inflamm Intest Dis 2017;2:131-8. [PMID: 30018964 DOI: 10.1159/000481400] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
83 Liu A, Chen M, Kumar R, Stefanovic-Racic M, O'Doherty RM, Ding Y, Jahnen-Dechent W, Borghesi L. Bone marrow lympho-myeloid malfunction in obesity requires precursor cell-autonomous TLR4. Nat Commun 2018;9:708. [PMID: 29453396 DOI: 10.1038/s41467-018-03145-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
84 Mühl L, Becker E, Müller TM, Atreya R, Atreya I, Neurath MF, Zundler S. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol 2021;21:33. [PMID: 33482730 DOI: 10.1186/s12876-021-01604-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Zhang D, Ren YB, Wei K, Hong J, Yang YT, Wu LJ, Zhang J, Shi Z, Wu HG, Ma XP. Herb-partitioned moxibustion alleviates colon injuries in ulcerative colitis rats. World J Gastroenterol 2018; 24(30): 3384-3397 [PMID: 30122878 DOI: 10.3748/wjg.v24.i30.3384] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
86 Raad MA, Chams NH, Sharara AI. New and Evolving Immunotherapy in Inflammatory Bowel Disease. Inflamm Intest Dis. 2016;1:85-95. [PMID: 29922662 DOI: 10.1159/000445986] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
87 Zhou T, Sheng Y, Guan H. Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China. Adv Ther 2021;38:4233-45. [PMID: 34089502 DOI: 10.1007/s12325-021-01806-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Peyrin-Biroulet L, Lönnfors S, Roblin X, Danese S, Avedano L. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. J Crohns Colitis 2017;11:128-33. [PMID: 27481878 DOI: 10.1093/ecco-jcc/jjw138] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 9.8] [Reference Citation Analysis]
89 Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1385-1397. e10. [PMID: 27189910 DOI: 10.1016/j.cgh.2016.04.039] [Cited by in Crossref: 216] [Cited by in F6Publishing: 192] [Article Influence: 36.0] [Reference Citation Analysis]
90 Gelhorn HL, Balantac Z, Ambrose CS, Chung YN, Stone B. Patient and physician preferences for attributes of biologic medications for severe asthma. Patient Prefer Adherence 2019;13:1253-68. [PMID: 31440040 DOI: 10.2147/PPA.S198953] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
91 Bjerrum JT, Steenholdt C, Ainsworth M, Nielsen OH, Reed MA, Atkins K, Günther UL, Hao F, Wang Y. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Med 2017;15:184. [PMID: 29032767 DOI: 10.1186/s12916-017-0949-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
92 Mishra R, Dhawan P, Srivastava AS, Singh AB. Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. World J Stem Cells 2020; 12(10): 1050-1066 [PMID: 33178391 DOI: 10.4252/wjsc.v12.i10.1050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
93 Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14:22-31. [PMID: 27729659 DOI: 10.1038/nrgastro.2016.155] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 10.7] [Reference Citation Analysis]
94 Soroosh A, Fang K, Hoffman JM, Law IKM, Videlock E, Lokhandwala ZA, Zhao JJ, Hamidi S, Padua DM, Frey MR, Pothoulakis C, Rankin CR. Loss of miR-24-3p promotes epithelial cell apoptosis and impairs the recovery from intestinal inflammation. Cell Death Dis 2022;13. [DOI: 10.1038/s41419-021-04463-4] [Reference Citation Analysis]
95 Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, Brasier AR, Pinchuk IV, Tian B, Zhou J. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S38-62. [PMID: 34791293 DOI: 10.1093/ibd/izab190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
96 Li Y, Yang X, Yuan J, Lin R, Tian Y, Li Y, Zhang Y, Wang X, Xie Y, Wang S, Zheng X. Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway. Front Pharmacol 2022;13:819826. [DOI: 10.3389/fphar.2022.819826] [Reference Citation Analysis]
97 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
98 Cui J, Li Y, Jiao C, Gao J, He Y, Nie B, Kong L, Guo W, Xu Q. Improvement of magnesium isoglycyrrhizinate on DSS-induced acute and chronic colitis. Int Immunopharmacol 2021;90:107194. [PMID: 33290965 DOI: 10.1016/j.intimp.2020.107194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
99 Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1301-1315. [PMID: 28708806 DOI: 10.1097/mib.0000000000001199] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
100 Dmochowska N, Tieu W, Keller MD, Wardill HR, Mavrangelos C, Campaniello MA, Takhar P, Hughes PA. Immuno-PET of Innate Immune Markers CD11b and IL-1β Detects Inflammation in Murine Colitis. J Nucl Med 2019;60:858-63. [PMID: 30413657 DOI: 10.2967/jnumed.118.219287] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
101 Teich N, Bläker M, Holtkamp-Endemann F, Jörgensen E, Stallmach A, Hohenberger S. Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany. Inflamm Intest Dis 2021;6:48-60. [PMID: 33850839 DOI: 10.1159/000512159] [Reference Citation Analysis]
102 Adolph TE, Meyer M, Schwärzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35906289 DOI: 10.1038/s41575-022-00658-y] [Reference Citation Analysis]
103 Artom M, Czuber-Dochan W, Sturt J, Murrells T, Norton C. The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study. Aliment Pharmacol Ther. 2017;45:403-416. [PMID: 27868215 DOI: 10.1111/apt.13870] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
104 Kim JH, Cheon JH. Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis. Gut Liver 2016;10:162-3. [PMID: 26934881 DOI: 10.5009/gnl16024] [Reference Citation Analysis]
105 Eder P, Stawczyk-Eder K, Korybalska K, Czepulis N, Luczak J, Lykowska-Szuber L, Krela-Kazmierczak I, Linke K, Witowski J. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies. World J Gastroenterol 2017; 23(1): 135-140 [PMID: 28104989 DOI: 10.3748/wjg.v23.i1.135] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
106 Chapuis-Biron C, Kirchgesner J, Pariente B, Bouhnik Y, Amiot A, Viennot S, Serrero M, Fumery M, Allez M, Siproudhis L, Buisson A, Pineton de Chambrun G, Abitbol V, Nancey S, Caillo L, Plastaras L, Savoye G, Chanteloup E, Simon M, Dib N, Rajca S, Amil M, Parmentier AL, Peyrin-Biroulet L, Vuitton L; GETAID BioLAP Study Group. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.Am J Gastroenterol. 2020;115:1812-1820. [PMID: 33156100 DOI: 10.14309/ajg.0000000000000810] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
107 Dotan I, Allez M, Danese S, Keir M, Tole S, McBride J. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. Med Res Rev 2020;40:245-62. [PMID: 31215680 DOI: 10.1002/med.21601] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
108 Christophi GP, Rengarajan A, Ciorba MA. Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. Clin Exp Gastroenterol 2016;9:125-30. [PMID: 27274301 DOI: 10.2147/CEG.S80237] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
109 Peng C, Wu C, Xu X, Pan L, Lou Z, Zhao Y, Jiang H, He Z, Ruan B. Indole-3-carbinol ameliorates necroptosis and inflammation of intestinal epithelial cells in mice with ulcerative colitis by activating aryl hydrocarbon receptor. Exp Cell Res 2021;404:112638. [PMID: 34015312 DOI: 10.1016/j.yexcr.2021.112638] [Reference Citation Analysis]
110 Kim JY, Yoon H, Hwang JS, Yang SK, Park SH, Loftus EV Jr. Comparison of Disease-related Knowledge of Patients With Inflammatory Bowel Disease Between the West and the East Using an Updated Questionnaire (IBD-KNOW). J Clin Gastroenterol 2020;54:720-4. [PMID: 31764490 DOI: 10.1097/MCG.0000000000001283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
111 Huoponen S, Blom M. A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One 2015;10:e0145087. [PMID: 26675292 DOI: 10.1371/journal.pone.0145087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
112 Coskun M, Vermeire S, Nielsen OH. Novel Targeted Therapies for Inflammatory Bowel Disease. Trends Pharmacol Sci. 2017;38:127-142. [PMID: 27916280 DOI: 10.1016/j.tips.2016.10.014] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 13.8] [Reference Citation Analysis]
113 Bartneck M. Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis. Adv Drug Deliv Rev 2021;173:70-88. [PMID: 33774114 DOI: 10.1016/j.addr.2021.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
114 Zimmermann J, Durek P, Kühl AA, Schattenberg F, Maschmeyer P, Siracusa F, Lehmann K, Westendorf K, Weber M, Riedel R, Müller S, Radbruch A, Chang HD. The intestinal microbiota determines the colitis-inducing potential of T-bet-deficient Th cells in mice. Eur J Immunol 2018;48:161-7. [PMID: 28875499 DOI: 10.1002/eji.201747100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
115 Mizoguchi E, Subramaniam R, Okada T, Mizoguchi A. A Review of Selected IBD Biomarkers: From Animal Models to Bedside. Diagnostics (Basel) 2021;11:207. [PMID: 33573291 DOI: 10.3390/diagnostics11020207] [Reference Citation Analysis]
116 Mutalib M. Renal involvement in paediatric inflammatory bowel disease. Pediatr Nephrol 2021;36:279-85. [PMID: 31820145 DOI: 10.1007/s00467-019-04413-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Wang X, Yan J, Wang L, Pan D, Xu Y, Wang F, Sheng J, Li X, Yang M. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Theranostics 2020;10:10808-22. [PMID: 32929381 DOI: 10.7150/thno.47601] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
118 Ben-horin S, Mao R, Qiu Y, Chen M. Discontinuation of Biological Treatments in Inflammatory Bowel Disease: A Concise Pragmatic Review. Journal of Clinical Gastroenterology 2018;52:6-12. [DOI: 10.1097/mcg.0000000000000938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Linssen MD, Hooghiemstra WTR, Jorritsma-Smit A, Allersma DP, Dijkstra G, Nagengast WB. Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel Disease. Pharmaceuticals (Basel) 2021;14:922. [PMID: 34577622 DOI: 10.3390/ph14090922] [Reference Citation Analysis]
120 Patel D, Madani S, Patel S, Guglani L. Review of pulmonary adverse effects of infliximab therapy in Crohn's disease. Expert Opin Drug Saf 2016;15:769-75. [PMID: 26923135 DOI: 10.1517/14740338.2016.1160053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
121 Ahluwalia B, Moraes L, Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol 2018;53:379-89. [PMID: 29523023 DOI: 10.1080/00365521.2018.1447597] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 14.5] [Reference Citation Analysis]
122 Argollo M, Gilardi D, Roda G, Fiorino G, Peyrin-biroulet L, Danese S. Anti-fibrotic Drugs for Crohn’s Disease: Ready for Prime Time? CPD 2019;25:47-56. [DOI: 10.2174/1381612825666190308100844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
123 Rencz F, Gulácsi L, Péntek M, Gecse KB, Dignass A, Halfvarson J, Gomollón F, Baji P, Peyrin-Biroulet L, Lakatos PL, Brodszky V. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert Rev Pharmacoecon Outcomes Res 2017;17:597-606. [PMID: 28434387 DOI: 10.1080/14737167.2017.1322509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
124 DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies. Curr Gastroenterol Rep 2016;18:13. [PMID: 26908281 DOI: 10.1007/s11894-016-0487-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
125 Gabbani T, Deiana S, Annese V. CT-P13: design, development, and place in therapy. Drug Des Devel Ther 2017;11:1653-61. [PMID: 28652703 DOI: 10.2147/DDDT.S109852] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
126 Quaresma AB, Coy CSR, Damião AOMC, Kaplan GG, Kotze PG. BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES. Arq Gastroenterol 2019;56:318-22. [DOI: 10.1590/s0004-2803.201900000-59] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
127 Annese V, Duricova D, Gower-rousseau C, Jess T, Langholz E. Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. ECCOJC 2016;10:216-25. [DOI: 10.1093/ecco-jcc/jjv190] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
128 Lerang F, Holst R, Henriksen M, Wåhlberg H, Jelsness-jørgensen L. Antitumour necrosis factor alpha treatment in Crohn’s disease: long-term efficacy, side effects and need for surgery. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2022.2042592] [Reference Citation Analysis]
129 Almuntashri F, Binyaseen K, Alkhotani A. Chronic Inflammatory Demyelinating Polyneuropathy in Patients With Crohn's Disease on Infliximab Therapy. Cureus 2021;13:e19041. [PMID: 34858738 DOI: 10.7759/cureus.19041] [Reference Citation Analysis]
130 Yoon SM, Haritunians T, Chhina S, Liu Z, Yang S, Landers C, Li D, Ye BD, Shih D, Vasiliauskas EA, Ippoliti A, Rabizadeh S, Targan SR, Melmed GY, McGovern DPB. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD. Inflamm Bowel Dis 2017;23:1382-93. [PMID: 28590340 DOI: 10.1097/MIB.0000000000001150] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
131 Santiago M, Dias CC, Alves C, Ministro P, Gonçalves R, Carvalho D, Portela F, Correia L, Lago P, Magro F. The Magnitude of Crohn's Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review. Inflamm Bowel Dis 2022:izab334. [PMID: 35179190 DOI: 10.1093/ibd/izab334] [Reference Citation Analysis]
132 Lee JWJ, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, Tan W, Khalili H, Clish C, Vlamakis H, Xavier RJ, Ananthakrishnan AN. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe 2021;29:1294-1304.e4. [PMID: 34297922 DOI: 10.1016/j.chom.2021.06.019] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
133 O'Connell L, Winter DC, Aherne CM. The Role of Organoids as a Novel Platform for Modeling of Inflammatory Bowel Disease. Front Pediatr 2021;9:624045. [PMID: 33681101 DOI: 10.3389/fped.2021.624045] [Reference Citation Analysis]
134 Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, DʼIncà R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annese V; PROSIT-BIO Cohort. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis 2017;23:233-43. [PMID: 28092307 DOI: 10.1097/MIB.0000000000000995] [Cited by in Crossref: 105] [Cited by in F6Publishing: 38] [Article Influence: 26.3] [Reference Citation Analysis]
135 Ma S, Zhang J, Liu H, Li S, Wang Q. The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease. Front Cell Dev Biol 2022;10:896591. [PMID: 35721513 DOI: 10.3389/fcell.2022.896591] [Reference Citation Analysis]
136 Shi Y, Zhou M, Yan J, Gong Z, Wu J, Chen Y, Chen Y. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling. Front Pharmacol 2020;11:593. [PMID: 32435194 DOI: 10.3389/fphar.2020.00593] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Conner EM, Reglinski J, Smith WE, Zeitlin IJ. Schiff base complexes of copper and zinc as potential anti-colitic compounds. Biometals 2017;30:423-39. [PMID: 28425040 DOI: 10.1007/s10534-017-0016-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
138 Kaunitz JD. Development of Monoclonal Antibodies: The Dawn of mAb Rule. Dig Dis Sci 2017;62:831-2. [PMID: 28181099 DOI: 10.1007/s10620-017-4478-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
139 Ko Y, Paramsothy S, Yau Y, Leong RW. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Aliment Pharmacol Ther 2021;54:292-301. [PMID: 34151447 DOI: 10.1111/apt.16436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
140 Nie K, Zhang C, Deng M, Luo W, Ma K, Xu J, Wu X, Yang Y, Wang X. A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn's Disease. Front Pharmacol 2022;13:870796. [PMID: 35517818 DOI: 10.3389/fphar.2022.870796] [Reference Citation Analysis]
141 Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016;44:684-692. [PMID: 27507790 DOI: 10.1111/apt.13757] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
142 Zhou X, Chen Q, Ma Y, Huang Y, Gou S, Xiao B. Porous Polymeric Microparticles as an Oral Drug Platform for Effective Ulcerative Colitis Treatment. Journal of Pharmaceutical Sciences 2019;108:2238-42. [DOI: 10.1016/j.xphs.2019.02.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
143 Shim HH, Ma C, Kotze PG, Seow CH, Al-Farhan H, Al-Darmaki AK, Pang JXQ, Fedorak RN, Devlin SM, Dieleman LA, Kaplan GG, Novak KL, Kroeker KI, Halloran BP, Panaccione R. Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. J Can Assoc Gastroenterol 2018;1:115-23. [PMID: 31294352 DOI: 10.1093/jcag/gwy013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
144 Annese V. Biosimilars in IBD: Similarity Breeds Contented Patients. Dig Dis Sci 2019;64:1399-400. [PMID: 30725297 DOI: 10.1007/s10620-019-05499-5] [Reference Citation Analysis]
145 Motaghi E, Ghasemi-Pirbaluti M, Zabihi M. Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison. Pharmacol Res 2019;139:120-5. [PMID: 30395950 DOI: 10.1016/j.phrs.2018.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
146 Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol 2017; 23(27): 4958-4967 [PMID: 28785150 DOI: 10.3748/wjg.v23.i27.4958] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
147 Ben-shatach Z, Ziv-baran T, Fudim E, Yavzori M, Picard O, Levartovsky A, Selinger L, Weiss B, Kopylov U, Eliakim R, Ungar B. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. Therap Adv Gastroenterol 2022;15:175628482210833. [DOI: 10.1177/17562848221083395] [Reference Citation Analysis]
148 Sorrentino D, Nguyen V, Henderson C, Bankole A. Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link. Inflamm Bowel Dis. 2016;22:2527-2537. [PMID: 27575494 DOI: 10.1097/mib.0000000000000867] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
149 Hong ST, Koh B, Choi SJ, Yoon E, Pyo MC, Choi JW, Kim MS, Lee EJ, Paik KC, Han MS, Chun HJ, Heo JN, Kim ES, Cho BR. Two-Photon Probe for TNF-α. Assessment of the Transmembrane TNF-α Level in Human Colon Tissue by Two-Photon Microscopy. Anal Chem 2019;91:15769-76. [PMID: 31663332 DOI: 10.1021/acs.analchem.9b04036] [Reference Citation Analysis]
150 Peluso MJ, Chen J, Munter S, Reed A, Teraoka J, Eshun-Wilson I, Henrich TJ, Chin-Hong PV. Outcomes of immunomodulatory and biologic therapy in people living with HIV. AIDS 2020;34:1171-9. [PMID: 32310901 DOI: 10.1097/QAD.0000000000002549] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
151 Hansson-Hedblom A, Almond C, Borgström F, Sly I, Enkusson D, Troelsgaard Buchholt A, Karlsson L. Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden. Cost Eff Resour Alloc 2018;16:28. [PMID: 30123097 DOI: 10.1186/s12962-018-0114-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Park EJ, Myint PK, Appiah MG, Darkwah S, Caidengbate S, Ito A, Matsuo E, Kawamoto E, Gaowa A, Shimaoka M. The Spike Glycoprotein of SARS-CoV-2 Binds to β1 Integrins Expressed on the Surface of Lung Epithelial Cells. Viruses 2021;13:645. [PMID: 33918599 DOI: 10.3390/v13040645] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
153 Dos Santos AM, Carvalho SG, Meneguin AB, Sábio RM, Gremião MPD, Chorilli M. Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives. J Control Release 2021;334:353-66. [PMID: 33901582 DOI: 10.1016/j.jconrel.2021.04.026] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53:989-998. [PMID: 29980848 DOI: 10.1007/s00535-018-1479-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
155 Hall V, Johnson D, Torresi J. Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. J Travel Med 2018;25. [PMID: 29635641 DOI: 10.1093/jtm/tay018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
156 Zhang C, Shu W, Zhou G, Lin J, Chu F, Wu H, Liu Z. Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease. Mediators Inflamm 2018;2018:3021863. [PMID: 30595666 DOI: 10.1155/2018/3021863] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
157 Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 2018;11:215-26. [PMID: 29844695 DOI: 10.2147/JIR.S165330] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
158 Heim X, Joshkon A, Bermudez J, Bachelier R, Dubrou C, Boucraut J, Foucault-Bertaud A, Leroyer AS, Dignat-George F, Blot-Chabaud M, Bardin N. CD146/sCD146 in the Pathogenesis and Monitoring of Angiogenic and Inflammatory Diseases. Biomedicines 2020;8:E592. [PMID: 33321883 DOI: 10.3390/biomedicines8120592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16:1277-1290. [PMID: 27329436 DOI: 10.1080/14712598.2016.1203897] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
160 Arkteg CB, Goll R, Gundersen MD, Anderssen E, Fenton C, Florholmen J. Mucosal gene transcription of ulcerative colitis in endoscopic remission. Scand J Gastroenterol 2020;55:139-47. [PMID: 31918598 DOI: 10.1080/00365521.2019.1710245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
161 Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol 2021;33:623-30. [PMID: 33470695 DOI: 10.1097/MEG.0000000000002076] [Reference Citation Analysis]
162 Han X, Ding S, Jiang H, Liu G. Roles of Macrophages in the Development and Treatment of Gut Inflammation. Front Cell Dev Biol 2021;9:625423. [PMID: 33738283 DOI: 10.3389/fcell.2021.625423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
163 de Bruyn M, Vandooren J, Ugarte-berzal E, Arijs I, Vermeire S, Opdenakker G. The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. Critical Reviews in Biochemistry and Molecular Biology 2016;51:295-358. [DOI: 10.1080/10409238.2016.1199535] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
164 Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1210-7. [PMID: 28445244 DOI: 10.1097/MIB.0000000000001117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
165 Hong S, Ju S, Yoo JW, Ha NC, Jung Y. Design and evaluation of IKK-activated GSK3β inhibitory peptide as an inflammation-responsive anti-colitic therapeutic. Biomater Sci 2021;9:6584-96. [PMID: 34582526 DOI: 10.1039/d1bm00533b] [Reference Citation Analysis]
166 Kotla NG, Rana S, Sivaraman G, Sunnapu O, Vemula PK, Pandit A, Rochev Y. Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives. Adv Drug Deliv Rev 2019;146:248-66. [PMID: 29966684 DOI: 10.1016/j.addr.2018.06.021] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 24.3] [Reference Citation Analysis]
167 Allner C, Melde M, Becker E, Fuchs F, Mühl L, Klenske E, Müller L, Morgenstern N, Fietkau K, Hirschmann S, Atreya R, Atreya I, Neurath MF, Zundler S. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterol 2020;20:103. [PMID: 32293299 DOI: 10.1186/s12876-020-01253-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
168 Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. J Crohns Colitis. 2016;10:1015-1023. [PMID: 27022161 DOI: 10.1093/ecco-jcc/jjw067] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
169 Scarozza P, Marafini I, Laudisi F, Troncone E, Schmitt H, Lenti MV, Costa S, Rocchetti I, De Cristofaro E, Salvatori S, Frezzati L, Di Sabatino A, Atreya R, Neurath MF, Calabrese E, Monteleone G. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. J Clin Med 2020;9:E385. [PMID: 32024071 DOI: 10.3390/jcm9020385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Dhaliwal A, Quinlan JI, Overthrow K, Greig C, Lord JM, Armstrong MJ, Cooper SC. Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview. Nutrients 2021;13:656. [PMID: 33671473 DOI: 10.3390/nu13020656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
171 Nielsen OH, Li Y, Johansson-lindbom B, Coskun M. Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease. Trends in Molecular Medicine 2017;23:362-74. [DOI: 10.1016/j.molmed.2017.02.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
172 van Erp LW, Groenen MJM, Heida W, Wisse J, Roosenboom B, Wahab PJ. Mobile application to monitor inflammatory bowel disease patients on intravenous biologic treatment: a feasibility study. Scand J Gastroenterol 2021;56:1414-21. [PMID: 34448665 DOI: 10.1080/00365521.2021.1966832] [Reference Citation Analysis]
173 Roberti R, Iannone LF, Palleria C, De Sarro C, Spagnuolo R, Barbieri MA, Vero A, Manti A, Pisana V, Fries W, Trifirò G, Naturale MD, Larussa T, De Francesco AE, Bosco V, Donato di Paola E, Citraro R, Luzza F, Bennardo L, Rodinò S, Doldo P, Spina E, Russo E, De Sarro G. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin 2020;36:1457-63. [PMID: 32573307 DOI: 10.1080/03007995.2020.1786681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
174 Gong Y, Lin Y, Zhao N, He X, Lu A, Wei W, Jiang M. The Th17/Treg Immune Imbalance in Ulcerative Colitis Disease in a Chinese Han Population. Mediators Inflamm. 2016;2016:7089137. [PMID: 26977120 DOI: 10.1155/2016/7089137] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
175 Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology 2020; 158: 1554-1573. e12. [PMID: 31926171 DOI: 10.1053/j.gastro.2020.01.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 27.5] [Reference Citation Analysis]
176 Marafini I, Di Fusco D, Dinallo V, Franzè E, Stolfi C, Sica G, Monteleone G, Monteleone I. NPD-0414-2 and NPD-0414-24, Two Chemical Entities Designed as Aryl Hydrocarbon Receptor (AhR) Ligands, Inhibit Gut Inflammatory Signals. Front Pharmacol 2019;10:380. [PMID: 31031628 DOI: 10.3389/fphar.2019.00380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
177 Mao Y, Han M, Chen C, Wang X, Han J, Gao Y, Wang S. A biomimetic nanocomposite made of a ginger-derived exosome and an inorganic framework for high-performance delivery of oral antibodies. Nanoscale 2021;13:20157-69. [PMID: 34846415 DOI: 10.1039/d1nr06015e] [Reference Citation Analysis]
178 Parikh J, Kerman DH, Garcia-buitrago MT. Adalimumab-induced apoptotic enteropathy. Colorectal Dis 2016;18:419-21. [DOI: 10.1111/codi.13282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
179 Nielsen OH, Seidelin JB, Ainsworth M, Coskun M. Will novel oral formulations change the management of inflammatory bowel disease? Expert Opin Investig Drugs 2016;25:709-18. [PMID: 26967267 DOI: 10.1517/13543784.2016.1165204] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
180 Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D’incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V, Saettone S, Tari R, Petruzzellis C, Meucci G, Imperiali G, Guglielmi FW, Mazzuoli S, Caserta L, Caterina Parodi M, Colli A, Ronchetti A, Pugliese D, Geccherle A, Rogai F, Milani S, Renna S, Cassinotti A, Andriulli A, Martino G, Scrivo B, Troncone E, Kohn A, Bertani L, Lorenzon G, Ghione S, Nardone O, Vecchi M, Bertani A, Bosani MA, Bezzio C, Salerno R; PROSIT Investigators. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases 2019;25:568-79. [DOI: 10.1093/ibd/izy264] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
181 Morita Y, Imai T, Bamba S, Takahashi K, Inatomi O, Miyazaki T, Watanabe K, Nakamura S, Yoshida A, Endo Y, Ohmiya N, Tsujikawa T, Andoh A. Clinical relevance of innovative immunoassays for serum ustekinumab and anti-ustekinumab antibody levels in Crohn's disease. J Gastroenterol Hepatol 2020;35:1163-70. [PMID: 31860733 DOI: 10.1111/jgh.14962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Xu F, Liu Y, Wheaton AG, Rabarison KM, Croft JB. Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States. Appl Health Econ Health Policy 2019;17:77-91. [PMID: 30259396 DOI: 10.1007/s40258-018-0432-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
183 Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:162-175. [PMID: 29205406 DOI: 10.1111/apt.14422] [Cited by in Crossref: 139] [Cited by in F6Publishing: 121] [Article Influence: 27.8] [Reference Citation Analysis]
184 Ylisaukko-Oja T, Torvinen S, Ventola H, Schmidt S, Herrala S, Kononoff J, Voutilainen M. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab. Scand J Gastroenterol 2019;54:726-32. [PMID: 31203693 DOI: 10.1080/00365521.2019.1627579] [Reference Citation Analysis]